YaFarm Technologies, Inc. (OTCPINK: YFRM) is pleased to announce that it has signed a definitive agreement to acquire the Integrative Stem Cell Institute (the ISCI). The ISCI is a pioneer in the field of cell-based regenerative medicine. Combining a world-class medical facility with a state-of-the-art laboratory, the ISCI provides investigational treatments to patients as part of clinical studies, while providing long-term follow up to advance these promising therapies. The acquisition of the ISCI provides the Company with an entry into stem cell research and treatment. With the advent of regenerative medicine, clinics such as the ISCI have taken the years of scientific research and started to apply them to treatment of patients.
iMing Corp (OTCPINK: IMNG) is a provider of high-definition web based television and video for the Chinese Market with the goal of being a leading provider of set-top boxes in Asia and expanding into North America and Europe. iMing Corp (OTCPINK: IMNG) is a leading technology solution provider of set-top boxes (STB), which supplies high-definition television through the Web (Web TV) in China, turning the internet into the content delivery source which is displaying on their television or monitor. The content can be stored on internal storage or through external storage and also played on the system, but the general principle is to access the content through the web for either live viewing of TV channels, movies, and programs or to download and view the content on demand.
Crown Marketing (OTCQB: CWNM), Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas. Crown Marketing (OTCQB: CWNM) has recently announced that it is in discussions to grant non-exclusive licenses of its Controlled Drug Delivery Technology (CDDT) to Nutraceutical and Supplement Companies.
Crown Marketing has developed and patented a novel drug delivery device that has broad applications and benefits to the oral Rx medication and supplement market. The spectrum and reliability of pharmacokinetic profiles achievable with this technology appears to be superior to currently marketed formulations.
In addition to the benefit of a more effective drug delivery system, and by extension allowing for decreased dosages and the reduction of possible side effects, the cash cow for this company lies in its ability to potentially extend patent protection for the horde of multi-billion dollar blockbuster drugs facing the dreaded patent cliff.
Although 2012 might have been the year that the patent cliff reached its peak with $33 billion of sales at risk, the impact of loss of exclusivity will continue to reverberate across the decade, with more then $290 billion of prescription drug sales exposed to generic competition between now and 2018.
“This is the worst year, but it will also be bad in succeeding years,” said Jonathan de Pass, founder and CEO of EvaluatePharma, the consulting firm that compiled the data. The somewhat depressing conclusions of the report, World Preview 2018, were discussed at BIO 2012 on Tuesday, as the largest partnering-fest of the year got into its swing.
In the past 10 years, a huge amount of money has been thrown at acquisitions and the restructuring of research and development (R&D), in an attempt to replace the revenues that are under threat from patent expiries. Over the same time, EvaluatePharma estimated that $1.1 trillion has been invested in R&D in a bid to revitalize pipelines.
In 2010, the pharmaceutical industry had sales of $860 billion worldwide, up 3% from 2009. Just 133 blockbuster drugs accounted for $295 billion of those sales—about 34% of the market. Of those blockbusters, 13 are set to lose patent protection through 2017.
Crown’s technology will allow drug companies to modify the delivery, pharmacokinetics and dosage that, in addition to significantly reducing or eliminating side effects, would be patentable. New patents can run for 20 years.
Cholesterol fighter Lipitor held the title “best selling drug” for a few years, and had been a major source of income for the world’s biggest drug company, Pfizer.
Lipitor (atorvastatin) was released in 1998, and by 2006 it had reached worldwide peak sales of $12.9 billion, accounting for 27% of the company’s revenue.
In 2010, with $10.8 billion in sales, Lipitor still accounted for 15.8% of Pfizer’s total revenue. Unfortunately, Lipitor lost its patent protection, cutting Pfizer’s total net income by 50%. Pfizer’s CEO Ian Read stated on January 31, 2012, in USA TODAY: “Patent losses cost the company $5 billion dollars.”
If Crown can rejuvenate ageing pharmaceutical assets to counteract generic threats and preserve market share and income streams, it could become one of the more successful specialty pharmaceutical companies in memory.
Pharmaceutical companies desperately need to protect their revenue streams especially as they quickly approach the end of their patent life, as this is when their products are most profitable. For that reason, upfront and milestone payments should be significant and commensurate to the perceived value brought to the project by adopting CDDT technology.
In addition to milestone payments, royalties would continue for the life of the newly patented product. For drug delivery companies, royalty rates are generally accepted to be in the 7% to 12% range depending on the time and expense of adopting the extended release mechanism. Crown’s strong patent estate and low development costs for new formulations appears to provide for the least expensive and most expedient method for preserving patents and revenue streams.
OTPicks.com Is The #1 Source For Free Penny Stocks Alerts
This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. No representation, expressed or implied, is made as to the accuracy, completeness or correctness. We accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.
On Time Picks
SOURCE On Time Picks